$6.76
7.39% day before yesterday
Nasdaq, May 16, 09:48 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Stock price

$6.73
+0.53 8.55% 1M
-1.10 14.05% 6M
-1.31 16.29% YTD
-7.67 53.26% 1Y
-41.27 85.98% 3Y
-50.23 88.18% 5Y
-167.67 96.14% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.44 7.00%
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Key metrics

Market capitalization $1.09b
Enterprise Value $576.56m
P/E (TTM) P/E ratio 2.54
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.46
P/S ratio (TTM) P/S ratio 0.87
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 25.92%
Revenue (TTM) Revenue $1.25b
EBIT (operating result TTM) EBIT $422.81m
Free Cash Flow (TTM) Free Cash Flow $-196.61m
Cash position $742.16m
EPS (TTM) EPS $2.65
P/E forward 3.45
P/S forward 1.15
EV/Sales forward 0.61
Short interest 26.23%
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

4x Buy
57%
2x Hold
29%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

Buy
57%
Hold
29%
Sell
14%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,255 1,255
26% 26%
100%
- Direct Costs 161 161
54% 54%
13%
1,094 1,094
70% 70%
87%
- Selling and Administrative Expenses 243 243
39% 39%
19%
- Research and Development Expense 383 383
34% 34%
31%
468 468
240% 240%
37%
- Depreciation and Amortization 45 45
1% 1%
4%
EBIT (Operating Income) EBIT 423 423
212% 212%
34%
Net Profit 479 479
220% 220%
38%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
Reuters
about 8 hours ago
The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine.
Neutral
Seeking Alpha
3 days ago
Novavax, Inc. (NASDAQ:NVAX ) BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ET Company Participants John Jacobs - President and CEO Jim Kelly - CFO Ruxandra Draghia-Akli - EVP, Head, R&D Conference Call Participants Alec Stranahan - Bank of America Alec Stranahan Joining Day 2 of the 2025 Bank of America Healthcare Conference. My name is Alec Stranahan, Senior Biotech Analyst ...
Positive
Seeking Alpha
6 days ago
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven by $603M from terminated APA agreements and $19M from new vaccine shipments, indicating strong demand. Sanofi partnership converts lower-margin product revenue to higher-margin income, allowing Nov...
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today